Report: Current Stock Reports

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
May 18, 2023

Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
May 16, 2023

New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
May 11, 2023

Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
May 5, 2023

Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
April 20, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
April 12, 2023

Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV
April 6, 2023

Change of publication date of the annual report for 2022
March 10, 2023

Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors
March 2, 2023

Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification
February 6, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
February 3, 2023

Achievement of the first milestone under licence agreement with Exelixis Inc.
January 26, 2023

Announcement of the NDS on registration of series J shares with the NDS
January 25, 2023

Publication dates for periodic reports in 2023
January 25, 2023

Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company
January 25, 2023

Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE
January 20, 2023

Conditional registration of the series J shares of the Company with the National Depository for Securities
January 20, 2023

Notification from a shareholder of a change in its share in the total number of votes in the Company
January 19, 2023

Notification from a shareholder of a change in his share in the total number of votes in the Company
January 18, 2023